Related Experiment Video
Updated: May 31, 2026
Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
Published on: December 9, 2022
Potential biomarkers for monitoring therapeutic response in patients with CIDP
1Neuroimmunology Unit, Department of Pathophysiology, National University of Athens Medical School, 75 Mikras Asias Street, Athens, Greece. mdalakas@med.uoa.gr
Abstract:
Although the majority of patients with CIDP variably respond to intravenous immunoglobulin (IVIg), steroids, or plasmapheresis, 30% of them are unresponsive or insufficiently responsive to these therapies. The heterogeneity in therapeutic responses necessitates the need to search for biomarkers to determine the most suitable therapy from the outset and explore the best means for monitoring disease activity. The ICE study, which led to the first FDA-approved indication for IVIg in CIDP, has shown that maintenance therapy prevents relapses and axonal loss. In this paper, the multiple actions exerted by IVIg on the immunoregulatory network of CIDP are discussed as potential predictors of response to therapies. Emerging molecular markers, promising in identifying responders to IVIg from non-responders, include modulation of FcγRIIB receptors on monocytes and genome-wide transcription studies related to inflammatory mediators, demyelination, or axonal degeneration. Skin biopsies, Peripheral Blood Lymhocytes, CSF, and sera are accessible surrogate tissues for further exploring these molecules during therapies.
Insights
Identifying biomarkers is crucial for tailoring treatments for chronic inflammatory demyelinating polyneuropathy (CIDP). Research explores intravenous immunoglobulin (IVIg) actions and molecular markers to predict patient response and monitor disease activity.
Area of Science:
- Neurology
- Immunology
Background:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) affects many patients, with variable responses to standard treatments like intravenous immunoglobulin (IVIg), steroids, and plasmapheresis.
- A significant portion (30%) of CIDP patients exhibit insufficient response to these therapies, highlighting the need for personalized treatment strategies.
Purpose of the Study:
- To explore the immunoregulatory actions of IVIg in CIDP as potential predictors of therapeutic response.
- To identify emerging molecular markers for distinguishing IVIg responders from non-responders.
- To investigate accessible surrogate tissues for monitoring disease activity and therapeutic effects.
Main Methods:
- Review of the multiple actions of IVIg on the CIDP immunoregulatory network.
- Analysis of emerging molecular markers, including FcγRIIB receptor modulation on monocytes.
- Exploration of genome-wide transcription studies related to inflammation, demyelination, and axonal degeneration.
- Assessment of surrogate tissues such as skin biopsies, peripheral blood lymphocytes, CSF, and sera.
Main Results:
- IVIg exhibits multiple immunoregulatory actions in CIDP, suggesting potential as a predictive marker for treatment response.
- Modulation of FcγRIIB receptors on monocytes and specific transcriptional patterns show promise in differentiating IVIg responders.
- Accessible tissues offer viable avenues for exploring these molecular markers during therapy.
Conclusions:
- Identifying predictive biomarkers is essential for optimizing CIDP treatment selection and monitoring.
- Further research into molecular markers and IVIg's immunomodulatory effects can improve personalized therapy for CIDP patients.
- Accessible tissues provide a practical means for biomarker discovery and therapeutic monitoring in CIDP management.
